CR20150256A - Derivados de 5-fluoro-n-(piridin-2- amina que contienen un grupo sulfoximina - Google Patents
Derivados de 5-fluoro-n-(piridin-2- amina que contienen un grupo sulfoximinaInfo
- Publication number
- CR20150256A CR20150256A CR20150256A CR20150256A CR20150256A CR 20150256 A CR20150256 A CR 20150256A CR 20150256 A CR20150256 A CR 20150256A CR 20150256 A CR20150256 A CR 20150256A CR 20150256 A CR20150256 A CR 20150256A
- Authority
- CR
- Costa Rica
- Prior art keywords
- fluoro
- piridin
- amina
- derivatives
- sulfoximine group
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Derivados de 5-fluoro-N-(piridin-2-il)piridin-2-amina que contienen un grupo sulfoximina y que presentan la fórmula general (I), como se describen y definen en la presente. Métodos para prepararlas. Su uso en el tratamiento y/o la profilaxis de diversos trastornos, particularmente de los trastornos hiperproliferativos, de las enfermedades infecciosas inducidas por virus y/o de las enfermedades cardiovasculares. Compuestos intermediarios útiles para preparar los compuestos de fórmula general (I).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12192852 | 2012-11-15 | ||
| PCT/EP2013/073637 WO2014076091A1 (en) | 2012-11-15 | 2013-11-12 | 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfoximine group |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20150256A true CR20150256A (es) | 2015-07-01 |
Family
ID=47148672
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20150256A CR20150256A (es) | 2012-11-15 | 2015-05-15 | Derivados de 5-fluoro-n-(piridin-2- amina que contienen un grupo sulfoximina |
Country Status (43)
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6858615B2 (en) | 2002-02-19 | 2005-02-22 | Parion Sciences, Inc. | Phenyl guanidine sodium channel blockers |
| TW201636330A (zh) | 2011-05-24 | 2016-10-16 | 拜耳知識產權公司 | 含有硫醯亞胺基團之４－芳基－ｎ－苯基－１，３，５－三氮雜苯－２－胺 |
| AR086745A1 (es) | 2011-06-27 | 2014-01-22 | Parion Sciences Inc | 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida |
| CA2888383A1 (en) | 2012-10-18 | 2014-04-24 | Bayer Pharma Aktiengesellschaft | N-(pyridin-2-yl)pyrimidin-4-amine derivatives containing a sulfone group |
| JP6277195B2 (ja) | 2012-10-18 | 2018-02-07 | バイエル ファーマ アクチエンゲゼルシャフト | スルホン基を含んでいる５−フルオロ−ｎ−（ピリジン−２−イル）ピリジン−２−アミン誘導体 |
| US9650340B2 (en) | 2012-11-15 | 2017-05-16 | Bayer Pharma Aktiengesellschaft | 5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfoximine group |
| TW201418243A (zh) | 2012-11-15 | 2014-05-16 | Bayer Pharma AG | 含有磺醯亞胺基團之ｎ－（吡啶－２－基）嘧啶－４－胺衍生物 |
| CA2895512C (en) | 2012-12-17 | 2021-10-19 | Parion Sciences, Inc. | Chloro-pyrazine carboxamide derivatives useful for the treatment of diseases favoured by insufficient mucosal hydration |
| MX2015007797A (es) | 2012-12-17 | 2015-10-05 | Parion Sciences Inc | Compuestos de 3,5-diamino-6-cloro-n-(n-(4-fenilbutil) carbamimidoil) pirazin-2-carboxamida. |
| CA2917096C (en) * | 2013-07-04 | 2021-05-18 | Bayer Pharma Aktiengesellschaft | Sulfoximine substituted 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives and their use as cdk9 kinase inhibitors |
| US9102633B2 (en) | 2013-12-13 | 2015-08-11 | Parion Sciences, Inc. | Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds |
| WO2015136028A1 (en) | 2014-03-13 | 2015-09-17 | Bayer Pharma Aktiengesellschaft | 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group |
| CA2944251C (en) | 2014-04-01 | 2022-10-18 | Bayer Pharma Aktiengesellschaft | Disubstituted 5-fluoro pyrimidine derivatives containing a sulfondiimine group |
| AU2015243585B2 (en) | 2014-04-11 | 2019-08-01 | Bayer Pharma Aktiengesellschaft | Novel macrocyclic compounds |
| US9902716B2 (en) | 2014-10-16 | 2018-02-27 | Bayer Pharma Aktiengesellschaft | Fluorinated benzofuranyl-pyrimidine derivatives containing a sulfone group |
| US9884849B2 (en) | 2014-10-16 | 2018-02-06 | Bayer Pharma Aktiengesellschaft | Fluorinated benzofuranyl-pyrimidine derivatives containing a sulfoximine group |
| ES2786552T3 (es) | 2015-09-29 | 2020-10-13 | Bayer Pharma AG | Compuestos de sulfondiimina macrocíclicos nuevos |
| ES2819869T3 (es) | 2015-10-08 | 2021-04-19 | Bayer Pharma AG | Nuevos compuestos macrocíclicos modificados |
| WO2017060322A2 (en) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Ptefb-inhibitor-adc |
| EP3601236A1 (en) | 2017-03-28 | 2020-02-05 | Bayer Aktiengesellschaft | Novel ptefb inhibiting macrocyclic compounds |
| WO2018177899A1 (en) | 2017-03-28 | 2018-10-04 | Bayer Aktiengesellschaft | Novel ptefb inhibiting macrocyclic compounds |
| CA3090843A1 (en) * | 2018-02-13 | 2019-08-22 | Bayer Aktiengesellschaft | Use of 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-n-{4-[(s-methylsulfonimidoyl)methyl]pyridin-2-yl}pyridin-2-amine for treating diffuse large b-cell lymphoma |
| AU2020401999B2 (en) | 2019-12-09 | 2024-01-18 | Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. | Compound as cyclin-dependent kinase 9 inhibitor and use thereof |
| EP4114528A1 (en) * | 2020-03-06 | 2023-01-11 | Bayer Aktiengesellschaft | Imidazotriazines acting on cancer via inhibition of cdk12 |
| WO2022078309A1 (zh) * | 2020-10-12 | 2022-04-21 | 上海海雁医药科技有限公司 | 取代的二(吡啶-2-基)胺衍生物、其组合物及医药上的用途 |
| CN117015539A (zh) * | 2022-03-25 | 2023-11-07 | 成都苑东生物制药股份有限公司 | 一种氨基吡啶类衍生物、其制备方法及用途 |
| WO2024044757A1 (en) * | 2022-08-26 | 2024-02-29 | Sanford Burnham Prebys Medical Discovery Institute | Aminopyrimidine and aminotriazine derivatives as myc protein modulators |
| WO2024097179A1 (en) * | 2022-11-02 | 2024-05-10 | Vincerx Pharma, Inc. | Combination therapies comprising a cdk9 inhibitor for cancer |
| WO2024112656A1 (en) * | 2022-11-21 | 2024-05-30 | The Board Of Trustees Of The Leland Stanford Junior University | Use of a tyrosine kinase inhibitor for the treatment of hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA03005696A (es) | 2000-12-21 | 2003-10-06 | Glaxo Group Ltd | Pirimidinaminas como moduladores de angiogenesis. |
| DE10239042A1 (de) | 2002-08-21 | 2004-03-04 | Schering Ag | Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel |
| DE10349423A1 (de) | 2003-10-16 | 2005-06-16 | Schering Ag | Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
| US20090099160A1 (en) | 2004-12-17 | 2009-04-16 | David Andrews | 4-(4-(Imidazol-4-Yl) Pyrimidin-2-Ylamino) Benzamides as CDK Inhibitors |
| DE102006041382A1 (de) * | 2006-08-29 | 2008-03-20 | Bayer Schering Pharma Ag | Carbamoyl-Sulfoximide als Proteinkinaseinhibitoren |
| DE102006042143A1 (de) | 2006-09-08 | 2008-03-27 | Bayer Healthcare Aktiengesellschaft | Neue substituierte Bipyridin-Derivate und ihre Verwendung |
| WO2008060248A1 (en) | 2006-11-15 | 2008-05-22 | S*Bio Pte Ltd. | Indole sustituted pyrimidines and use thereof in the treatment of cancer |
| CN101568529A (zh) | 2006-12-22 | 2009-10-28 | 诺瓦提斯公司 | 作为cdk抑制剂、用于治疗癌症、炎症和病毒感染的杂芳基-杂芳基化合物 |
| JP2010514688A (ja) | 2006-12-22 | 2010-05-06 | ノバルティス アーゲー | インドール−４−イルピリミジニル−２−イル−アミン誘導体およびサイクリン依存性キナーゼ阻害剤としてのその使用 |
| US8436007B2 (en) | 2007-04-24 | 2013-05-07 | Ingenium Pharmaceuticals Gmbh | Inhibitors of protein kinases |
| WO2008129071A1 (en) | 2007-04-24 | 2008-10-30 | Ingenium Pharmaceuticals Gmbh | Inhibitors of protein kinases |
| EP2137166B1 (en) * | 2007-04-24 | 2012-05-30 | Ingenium Pharmaceuticals GmbH | 4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases |
| WO2008132138A1 (en) | 2007-04-25 | 2008-11-06 | Ingenium Pharmaceuticals Gmbh | Derivatives of 4,6-disubstituted aminopyrimidines |
| WO2009029998A1 (en) | 2007-09-06 | 2009-03-12 | Cytopia Research Pty Ltd | Retrometabolic compounds |
| GB0805477D0 (en) | 2008-03-26 | 2008-04-30 | Univ Nottingham | Pyrimidines triazines and their use as pharmaceutical agents |
| US8415381B2 (en) | 2009-07-30 | 2013-04-09 | Novartis Ag | Heteroaryl compounds and their uses |
| EP2550257B1 (en) | 2010-03-22 | 2016-12-21 | Lead Discovery Center GmbH | Pharmaceutically active disubstituted triazine derivatives |
| WO2012101063A1 (en) * | 2011-01-28 | 2012-08-02 | Novartis Ag | N-acyl pyridine biaryl compounds and their uses |
| ES2567066T3 (es) * | 2011-03-02 | 2016-04-19 | Lead Discovery Center Gmbh | Derivados de piridina disustituida farmacéuticamente activos |
| EP2527332A1 (en) * | 2011-05-24 | 2012-11-28 | Bayer Intellectual Property GmbH | 4-Aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group as CDK9 inhibitors |
| WO2013037894A1 (en) | 2011-09-16 | 2013-03-21 | Bayer Intellectual Property Gmbh | Disubstituted 5-fluoro pyrimidine derivatives containing a sulfoximine group |
| WO2013037896A1 (en) | 2011-09-16 | 2013-03-21 | Bayer Intellectual Property Gmbh | Disubstituted 5-fluoro-pyrimidines |
| JP6277195B2 (ja) * | 2012-10-18 | 2018-02-07 | バイエル ファーマ アクチエンゲゼルシャフト | スルホン基を含んでいる５−フルオロ−ｎ−（ピリジン−２−イル）ピリジン−２−アミン誘導体 |
| JP2015536311A (ja) | 2012-10-18 | 2015-12-21 | バイエル ファーマ アクチエンゲゼルシャフト | スルホン基を含有する４−（オルト）−フルオロフェニル−５−フルオロピリミジン−２−イルアミン |
| EP2920153B1 (en) | 2012-11-15 | 2017-02-01 | Bayer Pharma Aktiengesellschaft | 4-(ortho)-fluorophenyl-5-fluoropyrimidin-2-yl amines containing a sulfoximine group |
| US9650340B2 (en) | 2012-11-15 | 2017-05-16 | Bayer Pharma Aktiengesellschaft | 5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfoximine group |
| CA2917096C (en) | 2013-07-04 | 2021-05-18 | Bayer Pharma Aktiengesellschaft | Sulfoximine substituted 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives and their use as cdk9 kinase inhibitors |
| WO2015136028A1 (en) | 2014-03-13 | 2015-09-17 | Bayer Pharma Aktiengesellschaft | 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group |
-
2013
- 2013-11-12 US US14/443,279 patent/US9650340B2/en active Active
- 2013-11-12 DK DK13792885.9T patent/DK2928878T3/en active
- 2013-11-12 NZ NZ70708413A patent/NZ707084A/en unknown
- 2013-11-12 BR BR112015010707-9A patent/BR112015010707B1/pt active IP Right Grant
- 2013-11-12 JP JP2015542247A patent/JP6263193B2/ja active Active
- 2013-11-12 PT PT137928859T patent/PT2928878T/pt unknown
- 2013-11-12 AP AP2015008432A patent/AP3872A/en active
- 2013-11-12 CN CN201380070440.8A patent/CN105102444B/zh active Active
- 2013-11-12 SI SI201330389A patent/SI2928878T1/sl unknown
- 2013-11-12 MX MX2015006169A patent/MX2015006169A/es active IP Right Grant
- 2013-11-12 CA CA2891358A patent/CA2891358C/en active Active
- 2013-11-12 HU HUE13792885A patent/HUE032868T2/en unknown
- 2013-11-12 UA UAA201505911A patent/UA115254C2/uk unknown
- 2013-11-12 PE PE2015000630A patent/PE20151071A1/es active IP Right Grant
- 2013-11-12 RS RS20170009A patent/RS55580B1/sr unknown
- 2013-11-12 SG SG11201503079PA patent/SG11201503079PA/en unknown
- 2013-11-12 MA MA38090A patent/MA38090B1/fr unknown
- 2013-11-12 ES ES13792885.9T patent/ES2612978T3/es active Active
- 2013-11-12 AU AU2013346939A patent/AU2013346939B2/en active Active
- 2013-11-12 ME MEP-2017-16A patent/ME02880B/me unknown
- 2013-11-12 LT LTEP13792885.9T patent/LT2928878T/lt unknown
- 2013-11-12 WO PCT/EP2013/073637 patent/WO2014076091A1/en active Application Filing
- 2013-11-12 KR KR1020157015423A patent/KR102242871B1/ko active IP Right Grant
- 2013-11-12 EA EA201590890A patent/EA027226B1/ru not_active IP Right Cessation
- 2013-11-12 PL PL13792885T patent/PL2928878T3/pl unknown
- 2013-11-12 MY MYPI2015701520A patent/MY170609A/en unknown
- 2013-11-12 EP EP13792885.9A patent/EP2928878B1/en active Active
- 2013-11-13 JO JOP/2013/0330A patent/JO3332B1/ar active
- 2013-11-15 UY UY0001035141A patent/UY35141A/es not_active Application Discontinuation
- 2013-11-15 TW TW102141761A patent/TWI613193B/zh active
- 2013-11-15 AR ARP130104211A patent/AR093505A1/es active IP Right Grant
-
2015
- 2015-04-16 IL IL238322A patent/IL238322A/en active IP Right Grant
- 2015-05-05 PH PH12015501003A patent/PH12015501003B1/en unknown
- 2015-05-14 TN TNP2015000185A patent/TN2015000185A1/fr unknown
- 2015-05-14 CL CL2015001304A patent/CL2015001304A1/es unknown
- 2015-05-15 CR CR20150256A patent/CR20150256A/es unknown
- 2015-05-15 EC ECIEPI201519323A patent/ECSP15019323A/es unknown
- 2015-05-15 SV SV2015004979A patent/SV2015004979A/es unknown
- 2015-05-15 DO DO2015000118A patent/DOP2015000118A/es unknown
- 2015-05-15 CU CU2015000052A patent/CU20150052A7/es unknown
-
2016
- 2016-02-02 HK HK16101158.8A patent/HK1213255A1/zh unknown
- 2016-11-22 HR HRP20161547TT patent/HRP20161547T1/hr unknown
-
2017
- 2017-01-17 CY CY20171100053T patent/CY1118441T1/el unknown
- 2017-04-03 US US15/477,974 patent/US9877954B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20150256A (es) | Derivados de 5-fluoro-n-(piridin-2- amina que contienen un grupo sulfoximina | |
| CU20130157A7 (es) | 4 - aril- n- fenil- 1,3,5- triazin- 2- aminas que contienen un grupo sulfoximina | |
| DOP2015000117A (es) | Derivados de n-(piridin-2-il)pirimidin-4-amina que contienen un grupo sulfoximina | |
| UY35139A (es) | 4- (orto) -fluorofenil-5-fluoropirimidin-2-ilaminas que contienen un grupo sulfoximina | |
| DOP2016000278A (es) | Nuevos compuestos macrocíclicos | |
| WO2014060375A3 (en) | 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group | |
| BR112015007295A2 (pt) | processo para a preparação de compostos; compostos; e uso dos mesmos | |
| UY36938A (es) | Nuevos compuestos macrocíclicos modificados | |
| WO2014060493A3 (en) | N-(pyridin-2-yl)pyrimidin-4-amine derivatives containing a sulfone group | |
| UY36923A (es) | Nuevos compuestos macrocíclicos de sulfondiimina | |
| BR112014008616A2 (pt) | compostos antivirais | |
| BR112014015582A2 (pt) | compostos antivirais | |
| BR112015000392A2 (pt) | novos indazóis para o tratamento e profilaxia da infecção por vírus sincicial respiratório |